Landos Biopharma, Inc.
NLRX1 ligands
Last updated:
Abstract:
Provided are compounds that target the nucleotide-binding oligomerization domain, leucine rich repeat containing X1 (NLRX1) pathway. The compounds can be used to treat multiple conditions, including chronic and/or inflammatory gastrointestinal diseases, cancers, and infectious diseases.
Status:
Grant
Type:
Utility
Filling date:
7 Feb 2019
Issue date:
26 Nov 2019